One case of off-label drug use under the guidance of therapeutic drug monitoring
NIU Mengxi1,2,3,4 GUO Wei1,2,3,4
1.Department of Pharmacy, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
2.Beijing Key Laboratory of Mental Disorders, Beijing 100088, China;
3.the National Clinical Research Center for Mental Disorders, Beijing 100088, China;
4.Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100069, China
Abstract：A 71-year-old man with bipolar disorder had taken various antidepressants intermittently for many years, but the curative effect is not good. On March 21, 2018, the symptoms were slightly relieved and no adverse reactions occurred after the prescriptions of Escitalopram, Mirtazapine and Oxazepam were given in the outpatient clinic of Beijing Anding Hospital, Capital Medical University ("our hospital" for short). On April 11, 2018, the patient was hospitalized for further therapeutic effects. After admission, Lithium Carbonate, Sodium Valproate and Escitalopram were administered. Based on the actual treatment of the patient, and combined with pharmacokinetics and pharmacodynamics, the clinical pharmacist and doctors decided to give off-label dose of Escitalopram under the therapeutic drug monitoring. Escitalopram reached a steady-state valley concentration of 51.5 ng/mL (the concentration range of reference therapeutic was 15-80 ng/mL) after 2 weeks. After that, the patient′s plasma drug concentration remained stable, and the symptoms continued to relieve. Finally the patient achieved clinical improvement and discharged. In this case, based on Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017, the clinical pharmacist developed individualized doses for elderly patients with poor conventional dose therapy. Therapeutic drug monitoring in the case of overdosing ensured patient safety as well as efficacy.
牛梦溪1,2,3,4 果伟1,2,3,4. 在治疗药物监测指导下超说明书用药一例[J]. 中国医药导报, 2019, 16(26): 148-151.
NIU Mengxi1,2,3,4 GUO Wei1,2,3,4. One case of off-label drug use under the guidance of therapeutic drug monitoring. 中国医药导报, 2019, 16(26): 148-151.
[1] 司继刚.超说明书用药致医疗投诉实例分析与对策[J].实用药物与临床，2015，18（9）：1136-1139.
[2] 刘丹，曾圣雅，周吉银.临床科研超说明书用药问题及对策[J].中国医学伦理学，2018，31（11）：1317-1380.
[3] 赵晓彦，刘秀平，王君，等.精神科超说明书用药现状分析与探讨[J].中国医院用药评价与分析，2016，16（4）：560-563.
[4] Ladanie A，Ioannidis JPA，Stafford RS，et al. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials [J]. J Clin Epidemiol，2018，94：35-45.
[5] 黄亮，张伶俐，曾力楠，等.我院超说明书用药管理体系构建的实践与探索[J].中国药房，2019，30（1）：1-5.
[6] Wong J，Motulsky A，Abrahamowicz M，et al. Off-label indications for antidepressants in primary care：Descriptive study of prescriptions from an indication based electronic prescribing system [J]. BMJ，2017，356：j603.
[7] Vijay A，Becker JE，Ross JS，et al. Patterns and predictors of off-label prescription of psychiatric drugs [J]. PLoS One，2018，13（7）：e0198363.
[8] Tsuchimine S，Ochi S，Tajiri M，et al. Effects of Cytochrome P450（CYP）2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression [J]. Ther Drug Monit，2018，40（3）：356-361.
[9] 中华医学会精神医学分会老年精神医学组.老年期抑郁障碍诊疗专家共识[J].中华精神科杂志，2017，50（5）：329-334.
[10] Hiemke C，Bergemann N，Clement HW，et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology：Update 2017 [J]. Pharmacopsychiatry，2017，51（1-2）：9-62.
[11] Gerlach M，Egberts K，Dang SY，et al. Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry [J]. Expert Opin Drug Saf，2016，15（11）：1477-1482.
[12] Chen W，Cepoiu-Martin M，Stang A，et al. Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth：A Population-Based Study in Alberta，Canada [J]. Clin Drug Investig，2018，38（5）：449-455.
[13] 中华医学会.中国抑郁障碍防治指南[M].北京：中华医学电子音像出版社，2015.
[14] Stahl SM. Stahl精神药理学精要：神经科学基础与临床应用[M].3版.北京：北京大学医学出版社，2011.
[15] Savaskan E，Müller SE，B?觟hringer A，et al. Antidepressive therapy with escitalopram improves mood，cognitive symptoms，and identity memory for angry faces in elderly depressed patients [J]. Int J Neuropsychopharmacol，2008， 11（3）：381-388.
[16] Gorwood P，Weiller E，Lemming O，et al. Escitalopram prevents relapse in older patients with major depressive disorder [J]. Am J Geriatr Psychiatry，2007，15（7）：581-593.
[17] Tsai MH，Lin KM，Hsiao MC，et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response [J]. Pharmacogenomics，2010，11（4）：537-546.
[18] Rao DN. The Clinical Pharmacokinetics of Escitalopram [J]. Clin Pharmacokinet，2007，46（4）：281-290.
[19] Pollock BG，Perel JM，Kirshner M，et al. S-mephenytoin 4-hydroxylation in older Americans [J]. Eur J Clin Pharmacol，1991，40（6）：609-611.
[20] Yin SJ，Ni YB，Wang SM，et al. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian，Hui and Han populations [J]. J Clin Pharm Ther，2012，37（3）：364-369.
[21] Kasper S，Lemming OM，De Swart H. Escitalopram in the Long-Term Treatment of Major Depressive Disorder in Elderly Patients [J]. Neuropsychobiology，2006，54（3）：152-159.
[22] Glotzbach RK，Preskorn SH. Brain concentrations of tricyclic antidepressants：Single-dose kinetics and relationship to plasma concentrations in chronically dosed rats [J]. Psychopharmacology，1982，78（1）：25-27.
[23] Paulzen M，Lammertz SE，Gründer G，et al. Measuring citalopram in blood and central nervous system：revealing a distribution pattern that differs from other antidepressants. [J]. Int Clin Psychopharmacol，2016，31（5）：300.
[24] Guo W，Guo GX，Sun C，et al. Therapeutic drug monitoring of psychotropic drugs in China：a nationwide survey [J]. Ther Drug Monit，2013，35（6）：816-822.
[25] 钱素云，杨梅.超说明书用药的现状及原则[J].中国小儿急救医学，2018，25（1）：1-3.
[26] Waring RH，Harris RM，Mitchell SC. Drug metabolism in the elderly：A multifactorial problem? [J]. Maturitas，2017， 100：27-32.
[27] 韩毅音，徐蓓，梅升辉，等.中国医院超说明书用药调查与对策研究[J].中国临床药理学杂志，2016，32（8）：756-758.
2019, Vol. 16 
京公网安备 11010502046598号